Product Name：Lixisenatide
CAS No.：320367-13-3；827033-10-3；1997361-87-1
Synonyms：利西拉來
Catalog No.：218P139
Brand：HongTide（上海鴻肽生物）
Description：利西拉來（Lixisenatide）是目前用于治療糖尿病的藥物，并且也是GLP-1的受體激動(dòng)劑，本公司生產(chǎn)的是多肽產(chǎn)品，序列中含有44個(gè)氨基酸，是一條堿性多肽。利西拉來(Lyxumia)于2013年在歐洲獲得上市批準(zhǔn)，以利西拉來為主要原料的藥物屬注射用糖尿病治療藥物，一天注射一次，連同其它藥物或者胰島素一塊使用，適用于只能通過藥物來控制血糖水平的患者。
Lixisenatide is currently used to treat diabetes and is also a receptor agonist for GLP-1. What our company produces is a peptide, which contains 44 amino acids in its sequence and is a basic peptide. Lyxumia was approved for marketing in Europe in 2013. The drug with Lyxumia as the main raw material is a drug for diabetes injection, which is injected once a day, together with other drugs or insulin. It is applicable to patients who can only control the blood sugar level through drugs.
Purity (HPLC) ≥98.0%
Single impurity≤2%
Peptide content≥75.0%
Amino Acid Composition≤±15%
Bacterial Endotoxins≤50EU/mg
Solubility：H2O/DMSO
Vacuum-packed with aluminum foil bag or transparent bag.Various weights can be packed according to your requirements.
Storage:Cool dry place( Store at -20°C, away from the light)
Remark:For Research Use Only. Not for human use.
Sequence(1-letter code) | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2 |
Sequence(3-letter code) | H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2 |
Peptide Structure | 
|
Molecular Formula | C215H347N61O65S |
Molecular Weight | 4858.56 |
訂購(gòu)聯(lián)系方式：
上海鴻肽生物科技有限公司
手機(jī)： +86-18018095145 （同微信號(hào)）
QQ: 3259098395
郵箱：sales1@hongtide.com
關(guān)鍵字： 320367-13-3;827033-10-3;1997361-87-1;利西拉來;Lixisenatide;
上海鴻肽生物科技有限公司（簡(jiǎn)稱：鴻肽生物）是一家以多肽以及多肽上下游產(chǎn)品研發(fā)、生產(chǎn)、銷售以及技術(shù)轉(zhuǎn)讓為主要業(yè) 務(wù)科技公司。公司現(xiàn)有產(chǎn)品涵蓋：定制多肽、目錄多肽、氨基酸衍生物、小分子化合物；公司自成立以來，秉持“用質(zhì)量作船， 以服務(wù)為帆，為科研服務(wù)”的企業(yè)理念，為國(guó)內(nèi)外眾多科研工作者提供了優(yōu)質(zhì)的服務(wù)及產(chǎn)品。